This balance is hypothesized to maximize metabolic benefits while potentially reducing the severity of GLP-1-mediated gastrointestinal side effects
21, 2025, the FDA determined that the semaglutide shortage is over, giving compounding pharmacies a deadline for ceasing the distribution of compounded versions of injectable semaglutide that are essentially identical to FDA-approved versions (e.g., Wegovy and Rybelsus)
TSA does not require it, but a brief letter from your licensed healthcare provider confirming the medication is prescribed can reducethe chance of delays
This could lead to broader changes in population health management and overarching changes in health system needs
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications primarily used for managing type 2 diabetes and, in some formulations, for weight management in adults with BMI 30 kg/m or 27 kg/m with weight-related comorbidities
Thorough documentation is an important part of safely managing patients who use compounded GLP-1 medications
